PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-3.67
Negative P/E indicates losses - a classic Benjamin Graham warning sign. While possibly indicating turnaround potential, verify Debt-to-Equity and Current Ratio for financial stability.
2536.67
P/S above 5.0 - Speculative zone. Seth Klarman would demand extraordinary evidence of future profitability. Examine all growth and margin metrics.
1.46
P/B 1.0-1.5 - Fair value territory. Peter Lynch would check if growth and ROE justify paying above book value. Examine asset turnover.
4.13
P/FCF under 10 - Deep value territory. Warren Buffett would verify cash flow sustainability. Cross-check Operating Cash Flow and Working Capital trends.
4.09
P/OCF under 8 - Deep value territory. Warren Buffett would verify operating cash flow quality. Cross-check Working Capital management and Free Cash Flow conversion.
1.46
Price above 140% of fair value - Danger zone. Philip Fisher would require extraordinary growth evidence. Scrutinize all valuation inputs carefully.
-6.80%
Negative earnings yield indicates losses - a classic Benjamin Graham warning sign. Verify Operating Cash Flow and examine path to profitability.
24.22%
FCF yield below 3% - Danger zone. Philip Fisher would require extraordinary growth evidence. Examine all capital allocation metrics.